Clinical and biological prognostic factors in diffuse large B cell lymphoma
Large B cell lymphomas are very different, from a clinician’s point of view, from the indolent malignancies. A significant percentage can be cured with currently available combination chemotherapy regimens, but the problem remains that the majority of patients will die of their disease. It is therefore of crucial importance to find ways of distinguishing between patients who can be cured with standard therapy and those who require new treatment approaches. Only in this way can we hope to improve upon the present situation.
KeywordsInternational Prognostic Index International Index Clinical Prognostic Factor Extranodal Disease Immunoblastic Lymphoma
Unable to display preview. Download preview PDF.
- 15.Hermine O, Haioun C, Lepage E et al. Bcl-2 protein expression in aggressive non-Hodgkin’s lymphoma (NHL). A new adverse prognostic factor? Fifth International Conference on Malignant Lymphoma 1993; 28.Google Scholar
- 19.Shipp MA, Harris NL, Mauch PM. Non-Hodgkin’s Lymphomas. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principles & Practice of Oncology. Lippincot-Raven. 1997; Vol 2: 2165–2220.Google Scholar